At Compamed, TekniPlex Healthcare to Highlight Multilayer Tubing and PVC Alternatives, Among Other Solutions

TekniPlex Healthcare, which utilizes advanced materials science expertise to help deliver better patient outcomes, will be highlighting its wide array of healthcare solutions at Compamed, November 13-16 in Dusseldorf, Germany. At Hall 8B, Stand N02, the company will showcase solutions ranging from medical compounds and tubing for medical devices to its grid lacquer coated paper and coated Tyvek® constructions for device packaging.

In the area of multilayer tubing, TekniPlex Healthcare is well versed in developing solutions for the transfer of sensitive drug products that contain preservatives, proteins, or other active ingredients prone to absorbing into the walls or surfaces of conventional tubing options. Recent examples include patented multilayer tubing configurations that offer extremely low absorption properties to help extend the usable life of insulin and other unstable drug products, such as chemotherapy drugs. Another patented configuration, designed for fluid transfer of DMSO and other solvent suspensions, features a polypropylene-based outer layer providing safe product delivery in dual hormone delivery systems and advanced cell and gene therapy processes.

The company also will be displaying multi-lumen tapered tubes, manufactured from Pebax® polymer, for endoscopic biliary procedures. For ease of handling by clinicians, the 2050 mm (81 inch) tubes transition from 2.45 mm (0.096 inches) on the proximal end to 1.72 mm (0.068 inches) on the distal end, which accesses the bile duct in the small intestine. A guidewire lumen, contrast lumen and balloon inflation lumen traverse the length of the tube to perform complex, minimally invasive procedures. The lumens are as small as 0.4 mm (0.016 inches) to 1.10 mm (0.43 inches), and retain consistently tight tolerances throughout the length of the tube.

The company also will be highlighting its medical device packaging offerings, including a variety of grid lacquer coated paper specifications and coated Tyvek® options. Early next year, TekniPlex Healthcare will be opening a new facility in Madison, WI, significantly boosting its lamination capacity for a broad range of materials including PET, nylon, paper, foil, PE, EAA and ionomer, in both peelable and non-peelable structures. The plant’s new coating and lamination assets will increase capacity for an array of products such as coated Tyvek® and reinforced papers.

Another offering will be the company’s range of solvent-bondable thermoplastic elastomer (TPE) tubing produced with its proprietary compound formulations. An alternative to polyvinyl chloride (PVC), TekniPlex Healthcare’s range of thermoplastic elastomer compounds combine the performance benefit of vulcanized rubber with the processing properties of thermoplastics. Free of silicone, latex, phthalate and halogen, they are suitable for a wide variety of medical device tubing applications.

Medical Device News Magazine
Our publication is dedicated to bringing our readers the latest medical device news. We are proud to boast that our subscribers include medical specialists, device industry executives, investors, and other allied health professionals, as well as patients who are interested in researching various medical devices. We hope you find value in our easy-to-read publication and its overall purpose and objectives! Medical Device News Magazine is a division of PTM Healthcare Marketing, Inc. Pauline T. Mayer is the managing editor.

More News!

Data from clinical studies of STK-001 demonstrated clinical benefit for patients ages 2 to 18 years old, including reductions in seizures and improvements in cognition and behavior that support the potential for disease modificatio. Analysis of 72 patients treated in STK-001 clinical trials suggests that higher STK-001 drug exposure in brain leads to greater seizure reductions. Two-year data from the longest prospective natural history study of Dravet syndrome showed that, on average, patients experienced no meaningful improvement in convulsive seizure frequency and exhibited widening gaps in cognition and behavior despite treatment with the best available anti-seizure medicines.
"Exact Sciences is looking forward to presenting new evidence at SABCS that adds important perspectives to treating breast cancer patients and showing that some patients may be able to de-escalate treatments and still have positive outcomes," said Dr. Rick Baehner, Chief Medical Officer, Precision Oncology, Exact Sciences. "Every year, we build upon the precedent set by the Oncotype DX Breast Recurrence Score® test and its prognostic and predictive abilities to determine the chemotherapy benefit for specific breast cancer patients. We are pleased to see authorities expanding access to this test as we continue to develop key evidence in collaboration with some of the world's most prestigious, breast cancer-focused organizations."
Clozapine has been established as the most effective antipsychotic medication for treatment-resistant schizophrenia. However, it is significantly underutilized mainly due to the risk of developing agranulocytosis and the need to frequently monitor the absolute neutrophil count (ANC).
Dagi-Ben Noon, CEO of Inspira Technologies, reflects on the partnership's significance: "By Integrating our technology to oxygenate blood directly with Ennocure's infection prevention solutions, we are focusing on potentially improving patient outcomes in ICUs and paving the way for safer, more effective life-support treatments. This collaboration is expected to accelerate the development and broaden the implementation of our advanced technology."
The findings suggest that the novel, non-invasive genomic test can help physicians guide next steps for these patients, enabling them to potentially avoid unnecessary invasive procedures or accelerate time to appropriate treatment.

By using this website you agree to accept Medical Device News Magazine Privacy Policy